Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT06990867 · ClinicalTrials.gov registry record · Phase 2

Optimizing Reperfusion to Improve Outcomes and Neurologic Function

A Phase 2 study of Acute Ischemic Stroke, sponsored by Corxel Pharmaceuticals.

Recruiting
Registry status
Phase 2
Development phase
740
Enrollment target
20
Study locations

NCT06990867 is a Phase 2 study of Acute Ischemic Stroke that is actively recruiting participants, run by Corxel Pharmaceuticals. The registered enrollment target is 740 participants, above the 322-participant average among 25 other Acute Ischemic Stroke trials with a reported enrollment target (130% higher). The trial reports 20 study locations across 14 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT06990867, a Phase 2 study of Acute Ischemic Stroke, is actively recruiting participants, sponsored by Corxel Pharmaceuticals.

RECRUITING
Registry status
Phase 2
Development phase
740 participants
Enrollment target
20
Study locations

Study Summary

The goal of this study is to evaluate the safety and efficacy of JX10 versus placebo in participants with Acute Ischemic Stroke (AIS) who present for care within 4.5 to 24 hours. The main question the study aims to answer are: 1. JX10 improves functional outcomes as measured by the modified Rankin Scale score when compared with placebo following AIS. 2. Risk of symptomatic intracranial hemorrhage of JX10 in participants with AIS. During Part 1, participants will be randomized to JX 10 (1mg/kg, 3 mg/kg) or placebo. During Part 2, participants will receive JX10 (optimal dose chosen from Part 1) or placebo.

Conditions Studied

Acute Ischemic Stroke

Interventions

  • DRUG Placebo
  • DRUG JX10

Study Locations (20)

Other

  • Corxel Investigational Site - Ghent
  • Corxel Investigational Site - Blagoevgrad
  • Corxel Investigational Site - Burgas

California

  • Corxel Investigational Site - Long Beach
  • Corxel Investigational Site - Sacramento

Michigan

  • Corxel Investigational Site - Kalamazoo
  • Corxel Investigational Site - Traverse City

New York

  • Corxel Investigational Site - Great Neck
  • Corxel Investigational Site - New York

Texas

  • Corxel Investigational Site - Dallas
  • Corxel Investigational Site - Houston

Colorado

  • Corxel Investigational Site - Colorado Springs

District of Columbia

  • Corxel Investigational Site - Washington D.C.

Florida

  • Corxel Investigational Site - Delray Beach

Trial Details

FieldValue
Enrollment Target 740 participants
Start Date 2025-05-15
Est. Completion 2029-12-31
Phase Phase 2

Sponsor

Corxel Pharmaceuticals

4 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT06990867

The ClinicalTrials.gov registry entry for NCT06990867 describes a study currently listed as recruiting, categorized as Phase 2. The registered enrollment target is 740 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 322-participant average among 25 other Acute Ischemic Stroke trials with a reported enrollment target (130% higher). The listed sponsor is Corxel Pharmaceuticals, which has 4 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Acute Ischemic Stroke appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.

NCT06990867 reports 20 study locations spanning 14 distinct geographic areas - top geographies include Other, California, Michigan.

Frequently Asked Questions

What is clinical trial NCT06990867 about?

NCT06990867 is a clinical study titled "Optimizing Reperfusion to Improve Outcomes and Neurologic Function". The goal of this study is to evaluate the safety and efficacy of JX10 versus placebo in participants with Acute Ischemic Stroke (AIS) who present for care within 4.5 to 24 hours. The main question the study aims to answer are: 1. JX10 improves functional outcomes as measured by the modified Rankin...

What is the current status of trial NCT06990867?

This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 740 participants. The study started on 2025-05-15. Estimated completion is 2029-12-31.

What conditions does trial NCT06990867 study?

This clinical trial studies the following conditions: Acute Ischemic Stroke.

What interventions are being tested in trial NCT06990867?

The interventions under investigation include: Placebo (DRUG), JX10 (DRUG).

Who is sponsoring clinical trial NCT06990867?

This trial is sponsored by Corxel Pharmaceuticals, which has 4 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT06990867 being conducted?

This trial has 20 study locations across California, Colorado, District of Columbia, Florida, Illinois. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Acute Ischemic Stroke

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Acute Ischemic Stroke

All registered trials for this condition

California

All trials with a study site in California

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.